Abstract
TRAPS is a rare lifelong disease. Optimal treatment is not established but tends to rely either on corticosteroids with risks of known short and long term side effects or anti cytokine agents which are expensive, and both types of agents lead to higher risk of infection.
Highlights
To analyze treatments used and their responses in patients with clinical TRAPS associated with a pathogenic sequence variants (PSV) in TNFRSF1A enrolled in the Eurofever/Eurotraps registry
Of 22 patients on maintenance steroids 6 (27%) reported complete attack prevention but 14 (64%) were converted to biologic therapy. 37 patients received etanercept. 9 patients had a CR and 26 a partial response (PR). 10 remain on etanercept
Of the 27 who discontinued etanercept inadequate disease response was sole or contributory reason for discontinuing etanercept in 21 and side effects in 9. 20 patients converted to anti IL-1 therapy. 38 patients received anakinra. 34 (89%) reported a CR and 4 a PR. 92% remain on anakinra with a median treatment duration date of 23 months
Summary
OR10-005 - Treatment responses in TRAPS: Eurofever/ Eurotraps Introduction TRAPS is a rare lifelong disease. Optimal treatment is not established but tends to rely either on corticosteroids with risks of known short and long term side effects or anti cytokine agents which are expensive, and both types of agents lead to higher risk of infection. Objectives To analyze treatments used and their responses in patients with clinical TRAPS associated with a pathogenic sequence variants (PSV) in TNFRSF1A enrolled in the Eurofever/Eurotraps registry.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
